Cargando…

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Detalles Bibliográficos
Autores principales:	Lamanna, Nicole, Tam, Constantine, Jurczak, Wojciech, Kontos, Arrin, Konig, Heiko, Ruppert, Amy S., Tsai, Donald E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431162/ http://dx.doi.org/10.1097/01.HS9.0000971248.72436.2f

Ejemplares similares

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
por: Thompson, Philip A., et al.
Publicado: (2023)

An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents
por: Sadeghi, Amir, et al.
Publicado: (2020)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

1088 ejercicios en circuito
por: Saura Aranda, Jeroni
Publicado: (1997)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

The risk of post-polypectomy bleeding among patients receiving antithrombotic agents: A prospective observational study
por: Bozkurt, Hilmi, et al.
Publicado: (2021)

Impact of laparoscopic liver resection on bleeding complications in patients receiving antithrombotics
por: Fujikawa, Takahisa, et al.
Publicado: (2017)

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
por: Kessler, Chiara, et al.
Publicado: (2020)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

The Ninth Centenary of the University of Bologna: Bologna 1088-1988
por: Eco, Umberto, et al.
Publicado: (1988)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

1088 Provider and patient attitudes regarding adult pertussis vaccination
por: Suryadevara, Manika, et al.
Publicado: (2014)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
por: Herrin, Jeph, et al.
Publicado: (2021)

Postoperative bleeding after percutaneous transhepatic gallbladder drainage and aspiration in patients receiving antithrombotic therapy
por: Iwamoto, Takayuki, et al.
Publicado: (2023)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2
por: Tanaka, Kanta, et al.
Publicado: (2022)

Antithrombotic Agents and Cancer
por: Bruno, Annalisa, et al.
Publicado: (2018)

Nisin Induces Cytotoxicity and Apoptosis in Human Asterocytoma Cell Line (SW1088)
por: Zainodini, Nahid, et al.
Publicado: (2018)

The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy
por: Bond, Andrew J, et al.
Publicado: (2005)

A quality‐of‐life questionnaire for heavy menstrual bleeding in Thai women receiving oral antithrombotics: Assessment of the translated Menstrual Bleeding Questionnaire
por: Rodpetch, Tinaram, et al.
Publicado: (2021)

Major gastrointestinal bleeding and antithrombotics: Characteristics and management
por: Bouget, Jacques, et al.
Publicado: (2020)

Prediction and Prevention of Postpolypectomy Bleeding: Necessity of a Different Approach for Patients Using Antithrombotic Agents
por: Kim, Duk Hwan
Publicado: (2017)

Management of Antithrombotic Agents During Surgery or Other Kinds of Medical Procedures With Bleeding: The MARK Study
por: Gotoh, Seiji, et al.
Publicado: (2020)

Design of a Microfluidic Bleeding Chip to Evaluate Antithrombotic Agents for Use in COVID-19 Patients
por: Lakshmanan, Hari Hara Sudhan, et al.
Publicado: (2020)

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

1088. Evaluating the Timing of Antimicrobial Prophylaxis in Allogeneic and Autologous Hematopoietic Stem Cell Transplant
por: Gawrys, Gerard, et al.
Publicado: (2019)

1088. Extracorporeal Photopheresis and Infectious Complications in Patients with Chronic Graft Versus Host Disease
por: Ashraf, Nida, et al.
Publicado: (2020)

Risk factors for bleeding after dental extractions in patients receiving antithrombotic drugs - A case control study
por: Huang, Jinxia, et al.
Publicado: (2022)

Perioperative antithrombotic management of patients who receive direct oral anticoagulants during gastroenterological surgery
por: Fujikawa, Takahisa, et al.
Publicado: (2020)

Effects of Antithrombotic Treatment on Bleeding Complications of EBUS-TBNA
por: Gil, Hyun-Il, et al.
Publicado: (2021)

Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?
por: Uozumi, Takeshi, et al.
Publicado: (2021)

Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
por: Simonsson, Moa, et al.
Publicado: (2022)

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Eyre, T. A., et al.
Publicado: (2022)

Optimal Timing for Resuming Antithrombotic Agents and Risk Factors for Delayed Bleeding after Endoscopic Resection of Colorectal Tumors
por: Beppu, Kazuko, et al.
Publicado: (2014)

The Bleeding Risk after Endoscopic Ultrasound-Guided Fine Needle Aspiration in Patients Taking Antithrombotic Agents Is Not Negligible
por: Jang, Dong Kee, et al.
Publicado: (2018)

Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia
por: Aslan, Burcu, et al.
Publicado: (2022)

Management of Antithrombotic Agents in Oral Surgery
por: Martinez, Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4g3m2iclujrk0o07o6480pgv6a